Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer Series: Complex Patient Cases in Bladder Cancer
Course InformationAccess Materials The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
The goal of this application-based activity is to review patient cases associated with the treatment of bladder cancer to assist learners apply this information into clinical practice.
At the completion of this activity, the learner will be able to:
- Design a comprehensive treatment plan for patients with bladder cancer that incorporates immune system checkpoint inhibitors.
- Prepare patients for the emergence of treatment-related adverse effects through accurate patient education.
Robert Svatek, MD
Angela B. Smith, MD, MS
This activity is designed for urologists, medical oncologists, and other healthcare providers who care for patients with bladder cancer.
This educational series is supported by independent educational grants from:
- Bristol-Myers Squibb